Top

Published in:

01-06-2016 | Review Article

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Authors: Sanket S. Mehta, Maxilliano Gelli, Deepesh Agarwal, Diane Goéré

Published in: Indian Journal of Surgical Oncology | Issue 2/2016

Abstract

The combined treatment concept of cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown to be an efficient therapeutic option for selected patients with primary and secondary peritoneal carcinomatosis (PC). This strategy represents the standard of care for diseases like pseudomyxoma peritonei and peritoneal mesothelioma, and offers the best long-term results for PC from colorectal cancer. Despite these results, skepticism exists regarding this therapeutic approach partly because of its perceived high toxicity. In this article, we review the current evidence on complications that can occur after CRS and HIPEC and the risk factors associated with increased incidence of morbidity and mortality.

Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69–76CrossRefPubMed

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456CrossRefPubMed

Yan T, Welch L, Black D, Sugarbaker P (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834CrossRefPubMed

Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13(2):229–237CrossRefPubMed

Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432CrossRefPubMed

Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 139(1):20–26CrossRefPubMed

Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27(5):681–685CrossRefPubMed

Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, et al. (2008) Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 15(12):3422–3432CrossRefPubMed

Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414CrossRefPubMed

10.

Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy–a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14(8):2270–2280CrossRefPubMed

11.

Moran BJ (2006) Decision-making and technical factors account for the learning curve in complex surgery. J Public Health 28(4):375–378CrossRef

12.

Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. (1996) Pseudomyxoma peritonei syndrome. Adv Surg 30:233–280PubMed

13.

Casado-Adam A, Alderman R, Stuart OA, Chang D, Sugarbaker PH (2011) Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol 2011:468698PubMedPubMedCentral

14.

Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10(8):863–869CrossRefPubMed

15.

Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 106(5):1144–1153CrossRefPubMed

16.

Hansson J, Graf W, Pahlman L, Nygren P, Mahteme H (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 35(2):202–208CrossRefPubMed

17.

Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ (2011) Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 54(3):293–299CrossRefPubMed

18.

Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618CrossRefPubMed

19.

Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M (2010) Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol 2(1):36–43CrossRefPubMedPubMedCentral

20.

Downs-Canner S, Ding Y, Magge DR, Jones H, Ramalingam L, Zureikat A, et al. (2015) A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol 22(5):1651–1657CrossRefPubMed

21.

Lawrence VA, Hilsenbeck SG, Mulrow CD, Dhanda R, Sapp J, Page CP (1995) Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med 10(12):671–678CrossRefPubMed

22.

Preti V, Chang D, Sugarbaker PH (2012) Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract 2012:635314CrossRefPubMedPubMedCentral

23.

Sugarbaker P, Van der Speeten K, Stuart O, Chang D, Mahteme H (2012) Patient-and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH (ed) Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. Cine-Med, Connecticut

24.

Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH (2007) Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 96(2):102–112CrossRefPubMed

25.

Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E, et al. (2009) Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG 116(8):1062–1068CrossRefPubMed

26.

Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W (2008) Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol 109(2):303–307CrossRefPubMedPubMedCentral

27.

Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N (2007) Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol 96(6):507–513CrossRefPubMed

28.

Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6(8):790–796CrossRefPubMed

29.

Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P (2005) Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 31(1):53–58CrossRefPubMed

30.

Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J 15(3):196–199CrossRefPubMed

31.

Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, et al. (2004) Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 11(4):387–392CrossRefPubMed

32.

Muller H, Hahn M, Weller L, Simsa J (2008) Strategies to reduce perioperative morbidity in cytoreductive surgery. Hepato-Gastroenterology 55(86–87):1523–1529PubMed

33.

Schnake KJ, Sugarbaker PH, Yoo D (1999) Neutropenia following perioperative intraperitoneal chemotherapy. Tumori 85(1):41–46PubMed

34.

Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, et al. (2009) Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181–2187CrossRefPubMedPubMedCentral

35.

Becher RD, Shen P, Stewart JH, Russell G, Bradley JF, Levine EA (2011) Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol 2(2):70–76PubMedPubMedCentral

36.

Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179(1):e133–e139CrossRefPubMedPubMedCentral

37.

Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272CrossRefPubMed

38.

Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, et al. (2010) A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251(5):896–901CrossRefPubMed

39.

Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T (2014) The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 36(10):1486–1491CrossRefPubMed

40.

Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39(12):1435–1443CrossRefPubMed

41.

Vukadinovic V, Chiou JD, Morris DL (2015) Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience. Eur J Surg Oncol 41(5):702–706CrossRefPubMed

42.

Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, et al. (2005) Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 48(7):1372–1379CrossRefPubMed

43.

Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol 22(9):2958–2964CrossRefPubMed

44.

Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRefPubMed

45.

van Vugt JL, Braam HJ, van Oudheusden TR, Vestering A, Bollen TL, Wiezer MJ, et al. (2015) Erratum to: Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol 22 Suppl 3:1610

46.

Saxena A, Yan TD, Chua TC, Morris DL (2010) Critical Assessment of Risk Factors for Complications after Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. Ann Surg Oncol 17(5):1291–1301CrossRefPubMed

Title: Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases
Authors: Sanket S. Mehta
Maxilliano Gelli
Deepesh Agarwal
Diane Goéré
Publication date: 01-06-2016
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 2/2016
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-016-0504-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei

The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Anaesthetic Considerations in the Perioperative Management of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Safety considerations for Health care Workers involved in Cytoreductive Surgery and Perioperative chemotherapy

Desk of the Editor